New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
09:03 EDTDCTH, ATRSAntares Pharma announces resignation of CEO Wotton, names Hobbs as CEO
Antares Pharma (ATRS) announced the resignation of Paul K. Wotton, Ph.D. who informed the company’s Board of Directors that he will assume the position of CEO of a development stage biotechnology company. Wotton also has resigned from the Antares Board of Directors. Antares Pharma also announced today the appointment of Eamonn P. Hobbs to the position of President and CEO of the company effective immediately. Hobbs joined the Antares Board of Directors in August 2009 and has over 30 years of experience in the pharmaceutical, medical device, and combination products industry, including the medical specialty fields of radiology, vascular surgery, interventional cardiology, oncology and gastroenterology. Hobbs was previously the President and CEO of Delcath Systems (DCTH).
News For ATRS;DCTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
08:07 EDTDCTHDelcath Systems begins enrollment for Phase trial of Melphalan/IDS
Delcath Systems' intrahepatic cholangiocarcinoma study cohort of its expanded Global Phase 2 Clinical Trial Program of Melphalan/HDS for use in the treatment of patients with unresectable hepatocellular carcinoma - primary liver cancer, or HCC - has opened for patient enrollment. The ICC study will be conducted at the same hospitals in Europe participating in the company's Phase 2 HCC trial, and ICC enrollment is now open at Goethe University Hospital in Frankfurt, the Medical School Hannover and Jena University Hospital. Additional centers in Germany and the U.K. are expected to open for enrollment in the coming weeks.
May 18, 2015
10:01 EDTATRSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:03 EDTATRSAntares Pharma initiated with an Overweight at Piper Jaffray
Target $3.50.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use